Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy

• Published in: EJHaem Vol. 4; no. 3; pp. 690 - 694
• Main Authors: Bønløkke, Søren Thorgaard, Severinsen, Marianne Tang, Ommen, Hans Beier, Eriksen, Christian Fenger, Hvas, Anne‐Mette
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.08.2023; John Wiley and Sons Inc; Wiley
• Subjects: acute leukemia; Acute myeloid leukemia; Antifibrinolytic agents; Biochemistry; Bleeding; Blood groups; Blood platelets; Body mass index; Bone marrow; Chemotherapy; Clinical medicine; coagulation; Data collection; Disease prevention; Drug dosages; Electronic medical records; fibrinolysis; Haematologic Malignancy ‐ Myeloid; Hemoglobin; hemostasis; Information systems; Leukemia; Patients; Platelets; Prophylaxis; Risk factors; Statistical analysis; Thrombocytopenia; Thromboembolism; Thrombosis; Denmark; Aarhus Denmark; fibrinolysis; hemostasis; coagulation; acute leukemia
• ISSN: 2688-6146; 2688-6146
• DOI: 10.1002/jha2.699

Patients suffering from acute myeloid leukemia (AML) carry a high risk of serious bleeding complications due to severe thrombocytopenia for long periods of time during treatment. Prior to prophylactic platelet transfusion becoming the standard of care, intracranial bleeding was a major contributor to death in AML patients. However, despite prophylactic platelet transfusions, up to 79% of patients with AML experience clinically significant bleeding during treatment. Antifibrinolytics are effective and well tolerated hemostatic agents widely used in many patient groups, and in this study, we investigated the effect of low dose tranexamic acid (TXA) in patients with AML and thrombocytopenia. We compared bleeding and thrombosis between 113 thrombocytopenic AML patients receiving TXA 500 mg three times daily (n = 36) versus no‐TXA (n = 77). Clinical information was obtained systematically from electronic medical records, and laboratory data were collected from the laboratory information system. No difference was demonstrated in number of patients with at least one bleeding episode (TXA: 89% vs. no‐TXA: 93%, p = 0.60), median number of bleeding days (TXA: 2.5 days vs. no‐TXA 2.0 days, p = 0.30), bleeding location or transfusion needs between the two groups. However, platelet count was found to be a significant risk factor for bleeding, with a probability of bleeding of 35% with a platelet count below 5 × 109/L (logistic regression, p < 0.01). We found no difference in thromboembolic events between the two groups (TXA: 8% vs. no‐TXA 10%, p = 0.99). In conclusion, treatment with low dose TXA is safe, but we found no evidence to suggest that it reduces bleeding in AML patients with thrombocytopenia.